KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gains from Sales and Divestitures: 2012-2015

Historic Gains from Sales and Divestitures for Alnylam Pharmaceuticals (ALNY) over the last 4 years, with Dec 2015 value amounting to $159,122.

  • Alnylam Pharmaceuticals' Gains from Sales and Divestitures fell 68.11% to $159,122 in Q4 2015 from the same period last year, while for Dec 2015 it was $159,122, marking a year-over-year decrease of 68.11%. This contributed to the annual value of $159,122 for FY2015, which is 68.11% down from last year.
  • As of FY2015, Alnylam Pharmaceuticals' Gains from Sales and Divestitures stood at $159,122, which was down 68.11% from $499,000 recorded in FY2014.
  • Alnylam Pharmaceuticals' 5-year Gains from Sales and Divestitures high stood at $499,000 for FY2014, and its period low was $105,093 during FY2013.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $159,122 (2015), whereas its average is $254,405.
  • Its Gains from Sales and Divestitures has fluctuated over the past 5 years, first soared by 374.82% in 2014, then tumbled by 68.11% in 2015.
  • Over the past 4 years, Alnylam Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $141,740 in 2012, then dropped by 25.86% to $105,093 in 2013, then skyrocketed by 374.82% to $499,000 in 2014, then tumbled by 68.11% to $159,122 in 2015.